Navigation Links
Kuvan, Naglazyme and Aldurazyme Data to Be Presented at the 57th Annual Meeting of the American Society of Human Genetics
Date:10/17/2007

sion study reported safety and

efficacy data of the 24-week pivotal Phase 3 trial, followed by a

72-week extension study for a total of 96 weeks.

-- Endpoints included 12-minute-walk-test (12MWT), 3-minute-stair-climb

(3MSC), level of urinary glycosaminoglycans (GAGS) and pulmonary

function.

-- Patients receiving Naglazyme improved by a mean of 183 m +/- 26 m from

baseline to week 96 in the 12MWT (p<0.001).

-- The placebo group, which was switched to active drug at week 24,

improved by a mean of 117 m +/- 25 m from week 24 to week 96 (p<0.001).

-- Similar improvements in the rate of stairs climbed (3MSC) were also

observed (p<0.001).

-- A sustained reduction in urinary GAGs was observed in both treatment

groups.

-- Several pulmonary function measures showed improvement at Week 96,

including forced vital capacity (FVC), which improved 0.11 L +/- 0.05 L

(p=0.039) in the Naglazyme group from baseline and improved 0.07 L +/-

0.02 L (p<0.001) in the placebo/Naglazyme group from Week 24.

-- Safety data for the extension study was similar to that measured in the

first 24 weeks of treatment. The overall safety profile remained

favorable. Adverse events reported by the greatest number of patients

during the extension study included headache, cough, pyrexia, diarrhea,

arthralgia and extremity pain. None of the adverse events that

occurred during infusion were severe.

The following relevant posters will also be featured:

-- 2229 -- Safety of sapropterin dihydrochloride (sapropterin) in children

with phenylketonuria (PKU) on a phenylalanine (Phe)-restricted diet

(Grange)

-- 2230 -- Safety and efficacy of sapropterin dihydrochloride

(sapropterin) treatment over 22 weeks in patients with phenylketonuria

(PKU) (Randolph)

-- 2231 --
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Wisconsin Assembly passes capital investment bill, revised CAPCO program not presented
2. NameProtect releases annual list of top trademarkers
3. Doyle says new contracts saving state more than $16 million annually
4. Department of Commerce offers up to $1 million annually to aid tech entrepreneurs
5. Annual Bioethics Forum to explore genetic testing
6. Annual Conference Honors Tech Grant Winners
7. AG accuses BioCATT of violating meetings law
8. VC trends, company progress discussed at Mason Wells portfolio meeting
9. Beware the Dreaded Off-Site Technology Meeting
10. A disgusting video: U.S. companies sell out Americans
11. Northwestern Mutual, American Family make Computerworlds best IT workplaces
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... and NEW YORK , ... from its open-label pilot study of mazindol in children ... Development and Therapy in December 2014 . ... mazindol in children with attention deficit/hyperactivity disorder" ( Konofal ... 2014 Dec 1;8:2321-2332. eCollection 2014 ) shows ...
(Date:12/22/2014)... Dec. 22, 2014 GenomeDx Biosciences today announced ... Cancer Classifier, a genomic test for prostate cancer, was ... men managed by radical prostatectomy without adjuvant therapy. Although ... relatively uncommon, using tumor genomics to identify these men ... is an important advance. The study has been ...
(Date:12/19/2014)... PA (PRWEB) December 19, 2014 ... leading developer and manufacturer of needle-free injection technology, ... agreement with Immunomic Therapeutics, Inc. (“ITI”) for ITI ... device with its LAMP™ vaccine platform. , ... an exclusive Worldwide license to the Biojector®-2000 that ...
(Date:12/19/2014)... Bina Technologies, Inc. (Bina, Redwood ... have been acquired by Roche (SIX: RO, ROG; OTCQX: ... company that provides a big data platform for centralized ... for the academic and translational research markets.  Bina will ... continue to focus on development of their innovative genomic ...
Breaking Biology Technology:Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 2Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 3Study Published in European Urology Shows that the Decipher Prostate Cancer Classifier is Predictive of Rapid Metastasis in High-Risk Men who have had Prostate Surgery 2Study Published in European Urology Shows that the Decipher Prostate Cancer Classifier is Predictive of Rapid Metastasis in High-Risk Men who have had Prostate Surgery 3Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 2Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 3Bina Technologies is acquired by Roche. 2Bina Technologies is acquired by Roche. 3
... , , AIX-EN-PROVENCE, France, ... received 510K Clearance from the FDA for its Aixplorer(TM) ultrasound ... in the United States. Aixplorer is the only commercially ... based upon interaction between conventional longitudinal waves and shear waves ...
... CAMBRIDGE, Mass., Aug. 25 Peptimmune, Inc., a ... clinical trial to evaluate the safety, tolerability, pharmacokinetics, and ... Sclerosis (SP-MS). PI-2301 is a novel peptide copolymer ... diseases. , , The Phase Ib ...
... ... An Innovative Treatment for Multiple Sclerosis and Other Autoimmune Diseases , ... New York, NY/Rockville, MD (Vocus) August ... National Multiple Sclerosis Society,s subsidiary devoted to bridging the gap between research and drug ...
Cached Biology Technology:SuperSonic Imagine Receives FDA Approval for Aixplorer Ultrasound System 2SuperSonic Imagine Receives FDA Approval for Aixplorer Ultrasound System 3SuperSonic Imagine Receives FDA Approval for Aixplorer Ultrasound System 4Peptimmune Completes Phase Ib Study of PI-2301 in Multiple Sclerosis Patients, and Presentation at ECTRIMS 2009 2Peptimmune Completes Phase Ib Study of PI-2301 in Multiple Sclerosis Patients, and Presentation at ECTRIMS 2009 3Fast Forward, LLC and Amplimmune, Inc. Join Forces to Speed New Treatments to People with MS** 2Fast Forward, LLC and Amplimmune, Inc. Join Forces to Speed New Treatments to People with MS** 3Fast Forward, LLC and Amplimmune, Inc. Join Forces to Speed New Treatments to People with MS** 4
(Date:12/17/2014)... DENVER , Dec. 16, 2014  Automation ... is this more evident than at international borders. ... secure document scanners have allowed veteran travelers to ... Automated Passport Control (APC) Kiosks at an increasing ... the globe. According to ...
(Date:12/11/2014)... --Research and Markets , ... ) has announced the addition of the ... to their offering. One major ... technology. With continuous advances in technology, it is ... standard that meets the needs and expectations of ...
(Date:12/11/2014)... Dec. 10, 2014  That blood pressure plays a role ... Hypertension – the medical term for high blood pressure – ... and the inflatable cuff that,s used in measuring blood pressure ... there,s nothing new about hypertension, its triggers and its effects. ... the condition and the best ways to treat it. ...
Breaking Biology News(10 mins):Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4
... CITY, Aug. 31, 2009 Researchers at Huntsman Cancer Institute ... on Ewing,s sarcoma, an often deadly bone cancer that typically ... with poor outcomes have tumors with high levels of a ... chemotherapy. The research is published online today in the journal ...
... its usefulness in counting copies of duplicated genome sequences and ... study to be published Aug. 30 in Nature Genetics ... differ from one person to the next. The researchers ... Search Tool. The study is titled, "Personalized Copy Number and ...
... on the neural mechanisms involved in social behavior, neuroscientists ... the brain structure responsible for our sense of personal ... 30 issue of the journal Nature Neuroscience , ... social distance is an issue. The structure, the ...
Cached Biology News:New hope for deadly childhood bone cancer 2Counting duplicated genome segments now possible 2Counting duplicated genome segments now possible 3Caltech neuroscientists find brain region responsible for our sense of personal space 2Caltech neuroscientists find brain region responsible for our sense of personal space 3Caltech neuroscientists find brain region responsible for our sense of personal space 4
Rabbit polyclonal antibody to NMDA NR2B [Tyr1336]...
... Reagent A: MTT, (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrasodium bromide), ... that is cleaved by living cells to ... process requires active mitochondria, and even freshly ... of MTT. Reagent A is a component ...
Mouse polyclonal antibody to ALS2CR8 - amyotrophic lateral sclerosis 2 (juvenile) chromosome region, candidate 8...
Determin interaction of your protein with Echelons lipids...
Biology Products: